Abstract
Background Esophageal cancer is a serious threat to human health and causes a heavy economic burden. upper gastrointestinal imaging(UGI imaging), enhanced CT, Fecal occult blood Tumor markers such as test(FOBT) and CEA, CA125 and CA19-9 are widely used in the screening or preliminary diagnosis of esophageal cancer. However, false positive results such as UGI imaging will bring unnecessary mental pain, expensive examination costs, examination injuries and other adverse consequences. However, false negative results such as UGI imaging lead to delayed treatment, and patients will have to bear the adverse consequences of poor prognosis, high treatment costs, poor quality of life, and short survival time. It is urgent to find a convenient, economical and non-invasive diagnostic method to reduce the false negative rate and false positive rate of UGI imaging. The objective of this study was to evaluate the diagnostic value of YiDiXie™-SS and YiDiXie™-HS in esophageal cancer.
Patients and methods This study included 164 subjects (malignant group, n=105; Benign group, n=59 cases). The remaining serum samples of the subjects were collected and the sensitivity and specificity of the YiDiXi ™-SS and YiDiXie™-HS were evaluated using the YiDiXie™all-cancer detection kit.
Results The sensitivity of YiDiXie™-SS was 99.0% (95% CI: 94.8% - 100%) and its specificity was 62.7% (95% CI: 50.0% - 73.9%).
The sensitivity of YiDiXie™-HS was 92.3% (95% CI: 85.7% - 96.1%) and its specificity was 86.4% (95% CI: 75.5% - 93.0%). The sensitivity of YiDiXie™-SS in UGI imaging, enhanced CT, FOBT, CEA, CA125 and CA19-9 positive patients was 96.6% (95% CI: 82.8-99.8%) and 98.7% (95% CI: 93.1% - 99.9%), 100% (95% CI: 17.8% 100%), 100% (95% CI: 81.6% 100%), 100% (95% CI: 61.0% 100%), 100% (95%CI: 56.6%-100%); The specific degrees were 60.0% (95% CI: 23.1% 92.9%), 75.0% (95% CI: 30.1% 98.7%), 100% (95% CI: 5.1% 100%), 100% (95% CI: 43.9% - 100%), 100% (95% CI: 5.1% 100%), 50.0% (95% CI: 2.6% 97.4%). This means that the application of YiDiXie™-SS, without basically increasing the missed diagnosis of malignant tumors, reduced the false positive range of UGI imaging, enhanced CT, FOBT, CEA, CA125 and CA19-9 by 60.0% (95% CI: 23.1% - 92.9%), 75.0% (95% CI: 30.1% 98.7%), 100% (95% CI: 5.1% 100%), 100% (95% CI: 43.9% 100%), 100% (95% CI: 5.1% - 100%), 50.0% (95% CI: 2.6% 97.4%).
The sensitivity of YiDiXie™-HS in UGI imaging, enhanced CT, FOBT, CEA, CA125 and CA19-9 negative patients was 88.9% (95% CI: 56.5% - 99.4%), 92.6% (95% CI: 84.8% - 96.6%), 96.9% (95% CI: 84.3% - 99.8%), 92.6% (95% CI: 84.8% - 96.6%), 92.0% (95% CI: 84.5% - 96.1%), 91.3% (95% CI: 83.8% - 95.5%), respectively; The specific degrees were 60.0% (95% CI: 23.1% 92.9%), 87.3% (95% CI: 76.0% 93.7%), 80.0% (95% CI: 37.6% 99.0%), 89.1% (95% CI: 78.2% - 94.9%), 79.3% (95% CI: 61.6% 90.2%), 87.0% (95% CI: 75.6% 93.6%). This means that YiDiXie™-HS reduced false negatives for UGI imaging, enhanced CT, FOBT, CEA, CA125 and CA19-9 by 88.9% (95% CI: 56.5% - 99.4%), 92.6% (95% CI: 84.8% 96.6%), 96.9% (95% CI: 84.3% 99.8%), 92.6% (95% CI: 84.8% 96.6%), 92.0% (95% CI: 84.5% - 96.1%), 91.3% (95% CI: 83.8% 95.5%).
Conclusion YiDiXie™-SS significantly reduced the false-positive rate of UGI imaging, enhanced CT, FOBT, CEA, CA125 and CA19-9 without substantially increasing the delayed treatment of malignant tumors. YiDiXie™ -HS significantly reduced false negative rates for UGI imaging, enhanced CT, FOBT, CEA, CA125 and CA19-9. YiDiXie™-SS and YiDiXie™-HS have important diagnostic value in esophageal cancer, and are expected to solve the two problems of “too high false positive rate such as UGI imaging” and “too high false negative rate such as UGI imaging” in esophageal cancer.
Clinical trial number ChiCTR2200066840.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ChiCTR2200066840
Funding Statement
This work was supported by Shenzhen High-level Hospital Construction Fund, Clinical Research Project of Peking University Shenzhen Hospital (LCYJ2020002, LCYJ2020015, LCYJ2020020, LCYJ2017001).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of Peking University Shenzhen Hospital gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos